Panacea Biotec completes enrolment for made-in-India dengue vaccine phase III trial

Panacea Biotec Limited  has completed the enrolment of study participants for the phase III clinical trial of its tetravalent dengue vaccine candidate, DengiAll®, marking an important milestone in the development of the indigenous vaccine.

The company said the phase III trial, being conducted in collaboration with the Indian Council of Medical Research, has completed enrolment of 10,335 participants across India. The development follows the initiation of the trial, which was earlier disclosed by the company in August 2024.

With enrolment now complete, Panacea Biotec will continue to monitor each participant for a period of two years after administration of the investigational medicinal product, which includes either the vaccine or a placebo. The monitoring phase is aimed at evaluating the efficacy and immunogenicity of DengiAll®.

According to the company, DengiAll® is positioned to become India’s first indigenous single-shot dengue vaccine. The vaccine candidate is expected to enter the market by 2027, subject to successful trial outcomes and regulatory approvals.

Also read: Panacea Biotech gets $8.9-million additional vaccine orders from UNICEF



The update was shared by Panacea Biotec under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Panacea Biotec shares closed higher on the NSE at ₹383 on January 7, gaining ₹16.70 or 4.56%.